This update on antimicrobial recommendations for diabetic foot ulcer treatment is a consensus statement based on clinical trial evidence, review of international guidelines and expert opinion.
| INTRODUCTION
Foot ulceration and infection continue to represent an important source of morbidity in people with diabetes mellitus. 1, 2 In an acute presentation with diabetic foot infection (DFI), there is frequently a delay in the identification of the causative organism, which may compel use of empirical antibiotic(s). 3, 4 Whilst this allows the prompt initiation of antimicrobial therapy, it carries a risk of treatment failure, the selection of resistant organisms and complications related to drug toxicity and alteration of the host microbiome. 5 The lifetime risk of foot complication within the diabetic population is considered to be around 25%, 6 with a point prevalence of around 2% 7 and the development of a diabetes-related foot ulcer is associated with an increased risk of lower extremity amputation and death. [7] [8] [9] [10] In addition to these outcomes, diabetic foot ulceration is associated with hospital admission, prolonged inpatient length of stay and physical and psychological morbidity. 7, 8, 11 Sharp debridement of ulcers, combined with pressure offloading, management of infection and the involvement of a multidisciplinary team to optimise glycaemia, cardiovascular risk, assess potential revascularisation and surgical intervention are considered to be the basis of ulcer care. [12] [13] [14] [15] In order to promote wound healing and reduce risk of amputation, involvement of the multidisciplinary team is recommended early in the natural history of the ulcer.
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| IDENTIFICATION OF DFI
Establishing presence of infection is an important component of ulcer care. Not all ulcers are infected and given increasing antibiotic resistance and risk of antibiotic-related adverse events including diarrhoea and Clostridium difficile infection, the goal for antibiotic use in foot ulceration is to treat an active infective process, aiming to tailor therapy to the appropriate pathogen(s). 20 The presence of microbes within clinically non-infected ulcers does not influence rates of healing. 21 In the absence of infection, antibiotic therapy represents a risk for the selection of drug-resistant pathogens and therapeutic complications. [21] [22] [23] The identification of an infective process within a diabetic foot ulcer is predicated on clinical assessment combined with supportive investigations. [23] [24] [25] Inflammatory change within the ulcer bed and the presence of increasing exudate or pus is suggestive of infection. [24] [25] [26] The validity of these clinical factors has been challenged by a study which has shown poor correlation between microbial load and the presence of clinical signs. 22 However, the IDSA criteria have been validated as a useful tool for grading foot infections. 27, 28 Coexisting skin and/or soft tissue infection (SSTI) in association with the ulcer border also suggests an active infective process, usually seen as red, warm, swollen and inflamed skin. 3, [24] [25] [26] This may be accompanied by a change in odour from the ulcer or the development of pain (unusual in a neuropathic foot). 22, 28 The diagnosis of deep infection such as osteomyelitis is, despite the development of new imaging modalities, often made using serial plain radiography. 29, 30 The ability to probe to bone in an infected ulcer increases the likelihood that osteomyelitis is present, but is not pathognomonic of osteomyelitis. 14, 31 It is, however, an independent predictor of lower extremity amputation (LEA).
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The combination of both radiography and positive probe-to-bone has high sensitivity for the diagnosis of osteomyelitis. 32, 33 The removal of bone fragments during debridement is consistent with osteomyelitis and these fragments should be sent for culture in a sterile container. 34 Clinical findings such as a globally inflamed digit which has lost its usual contours and skin markings ("sausage" digit) also suggest underlying osteomyelitis but may also be observed in fracture or Charcot neuroarthropathy. 35, 36 Differentiation of infection vs Charcot neuroarthropathy is often clinically challenging, however detailed discussion of the exploration of these two diagnoses is beyond the scope of this article.
Further specific assessment of the infective burden associated with a foot ulcer can be categorised using the Infectious Disease Society of America (IDSA) grading tool ( Any infection with systemic toxicity (fever, shock, vomiting, confusion, metabolic instability). Presence of critical
| IMAGING IN THE DIAGNOSIS OF DFI
The sensitivity of plain X-ray in detecting osteomyelitis has been recorded at 54%, 29 but is much greater with serial plain X-ray. 43 The extent of deep tissue involvement including osteomyelitis may not be clinically apparent, even with the use of sterile metal probes and serial plain X-ray imaging. 30 The presence of a non-healing ulcer may raise clinical suspicion of deep tissue infection, although this was not a contributory factor in a recent study of chronic ulceration. 44 Both isotope white cell scans and triple phase bone scans are highly sensitive in detecting osteomyelitis and deep tissue infection but lack specificity (being unable to distinguish between inflammatory changes related to Charcot neuroarthropathy), anatomical resolution and may continue to show positive results for long periods after clinical resolution. 45, 46 MRI scanning is between 90% and 100% sensitive for osteomyelitis but alone, has a specificity of <80%. Imaging protocols which combine Single Positron Emission Computed Tomography (SPECT) and MRI may improve the sensitivity and specificity of detection of foot infection. 47 An alternative diagnostic combination using SPECT-CT scanning with the radioisotope 67 Ga and aseptic bone puncture results in even greater specificity (>93%) than hybrid SPECT/MRI. and infection. The presence of inflammatory infiltrates, bone loss and marrow oedema is observed in both conditions, but predominance of osteoclasts over osteoblasts is more indicative of Charcot neuroarthropathy. 35 Despite these limitations, the authors support the use of bone biopsy for pathogen detection or to resolve diagnostic uncertainty between infection and Charcot neuroarthopathy.
The development of local protocols which consider available imaging and surgical resource is recommended, based on bone sampling principles outlined in Figure 1 . [48] [49] [50] For forefoot ulcers complicated by osteomyelitis, use of MRI scanning in a small cohort was shown to support clinical decision-making, specifically duration of antibiotic therapy and requirement for surgical intervention. 51 Three-monthly MRI scanning was used to determine if an osteomyelitic bone signal had changed. Although the relapse rate (initial healing, followed by recurrence of a lesion) at 31 months was low (13%) compared with other studies, 52 this approach did promote prolonged antibiotic therapy (median 6 months, range 3-12). Other groups have reported resolution of osteomyelitis with much shorter courses of antibiotics 53, 54 and we would advise caution with the length of treatment as described.
| DIAGNOSTIC MICROBIOLOGY IN DFI
Wound bioburden in the absence of clinical infection should not result in the initiation of antimicrobial therapy. 21, 25 However, it is accepted that culture results may be limited by culturing/sampling techniques and previous antibiotic exposure. 21, 55 The role of polymicrobial infection and the degree to which microbe-produced biofilm influences culture results are controversial. It is likely that adherent biofilm produced by microbes such as S. aureus contributes to the antimicrobial resistance of the organism in acute infection. 56, 57 Biofilm may also shield other pathogens from detection, 58 as the combination of molecular techniques and deep tissue sampling often reveals a polymicrobial presence.
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A French group has utilised molecular techniques to determine the pathogenicity of microbes detected in foot ulcers. Oligonucleotide microarrays determining the expression of virulence factors from S. aureus combined with detection of S. aureus clones considered to be "actively infecting" show promise in establishing which ulcers contain a bioburden likely, or unlikely, to cause harm and therefore may help choose antibiotic therapy. 61 Further studies in small cohorts of people with diabetic foot ulcers have been performed by the same group. 62 These studies not only identify a much more diverse bacterial flora within the ulcer, but appear to be able to distinguish actively pathogenic organisms, from non-pathogenic or colonising organisms with pathogenic potential and have greater sensitivity in detecting pathogenic species in deep tissue samples. The presence of 'colonising' bacteria (with pathogenic potential) may be a predictor of relapsing foot infection or chronic persistent ulceration. 63, 64 The presence of additional-site methicillinresistant S. aureus carriage (eg, nasal/perineal) may also predispose to re-infection. 65, 66 These issues highlight known limitations in current 68 and a more diverse ulcer microbiome may contribute to reduced efficacy of antimicrobial therapy. 63, 64, 67 The use of molecular techniques shows potential to deliver more rapidly available results along with more comprehensive evaluation of the ulcer microbiome. 61, 62 However, the availability of advanced molecular diagnostics is limited in most NHS laboratories. There is also a paucity of outcome data available to illustrate whether a more complete description of the wound microbiome can direct more effective antimicrobial therapy and improve outcomes. In all cases, treatment of an infected diabetic foot lesion should be focused to a narrow spectrum of pathogen cover, ideally directed by culture results. 24, 25 Empirical antibiotic therapy is the first-line step for patients with more severe infection with sepsis or associated skin and soft tissue infection (Table 1) . Wherever possible, appropriate samples should always be sent for microbiological analysis before initiation of antibiotic therapy and this group would encourage use of historical microbiology results to influence choice of empirical therapy. In poorly healing or recurrent ulcers, the authors suggest that clinicians may also consider the use of screening cultures (eg, nose, perineum, throat swabs) to provide greater knowledge of the patient's own skin/ mucosal microbiome. These results have the potential to direct parallel eradication therapies (eg, MRSA) and allow an appreciation of reinfection risk. 65, 66 The decision to utilise antibiotic treatment may be supported using the algorithm in Figure 3 .
| ANTIBIOTIC THERAPY: RISKS, BENEFITS AND COMPLICATIONS
The International Working Group on the Diabetic Foot (IWGDF) has published comprehensive guidance on diabetic foot infections. 24 Whilst these guidelines represent the foundation of practice for treatment of DFI, national and regional variation in pathogens and antimicrobial susceptibility exist in the literature. 78, 79 The recommendations outlined in Table 2 reflect consensus on regional/national pathogens, antimicrobial Co-trimoxazole 7-10 days (including IV to oral switch) 14 days IV therapy if S. aureus bacteraemia Review need for Gram-negative cover and rationalise therapy depending on microbiology 4-6 weeks therapy (may require >6 weeks in non-surgically treated). Usually at least 2 weeks of IV therapy in acute setting but oral therapy may be suitable in non-acute setting Review need for Gram-negative cover and rationalise therapy depending on microbiology This is for guidance only and local practice/ guidance may vary. Infection specialist advice should be sought if any uncertainty. Targeted therapy based on good microbiological sampling is always preferred when available. Dosing of vancomycin, gentamicin and teicoplanin should be as per local guidance. Be aware of potential drug interactions with rifampicin, doxycycline, ciprofloxacin, metronidazole and linezolid. Dosing assumes normal renal and hepatic function. Please refer to BNF for dose adjustments.
T A B L E 2 (Continued) susceptibility and antibiotic availability ( Table 2) . For this reason, these recommendations may be of more practical use to UK-based clinicians.
The duration of antibiotic therapy remains a contentious subject.
Superficial SSTI can be assessed clinically and 1-2 weeks of therapy is usually adequate. 24, 25, 80, 81 However, deep-seated infection or osteomyelitis may require prolonged antibiotic therapy and further assessment may benefit from re-imaging (eg, MRI). 51 Traditional advice favouring 6-12 weeks of treatment with antibiotics for nonsurgically treated osteomyelitis is supported by heterogeneous data from retrospective studies. 25 There is inadequate evidence to support treatment beyond 6 weeks from randomised controlled trials. 80, 81 A recent French study suggested that resolution of osteomyelitis occurred in around two-thirds of patients treated for 6 weeks.
In this study, not all patients received intravenous antibiotics and many received narrow-spectrum therapy because of the use of bone sampling and avoidance of empirical therapy where clinically appropriate. 53 Both the 2012 IDSA and the 2016 IWGDF guidelines consider that a minimum of 4 weeks of antibiotic therapy is required in the presence of infected or necrotic bone. 20, 24, 25 In the absence of surgical intervention, 6 weeks of antibiotic therapy is suggested 24 although patients who do not undergo any surgical resection may need a longer duration. 24, 25 Retrospective analysis of clinical osteomyelitis treatment in a general diabetic foot ulcer population has shown resolution with medical treatment alone in 66.9% of cases. 82 Ulcers were considered healed with sustained skin closure at 3 months after antibiotic completion (Personal communication Rajbhandari SM, 2015) . Around 50% of these patients required multiple antibiotic courses. 82 A randomised controlled trial in a single specialist centre achieved similar (75%) healing rates in patients with forefoot osteomyelitis; these patients received medical treatment and showed comparable healing rates to those treated with a primarily surgical approach (86.3%, P = .33). Patients with peripheral arterial disease, exposed bone and poorly controlled diabetes (HbA1c >10%/85.8 mmol.mol
) were excluded. 83 These are all features common to "real-world" diabetes foot clinics. However, there is developing evidence that many diabetic foot ulcers with osteomyelitis can be managed by conservative, non-surgical treatment.
Studies are underway to assess whether the strategy of using oral therapy (usually utilising oral bio-available agents with appropriate spectrum of activity and good bone penetration) is non-inferior to traditional IV therapy in bone and joint infection (including diabetesassociated osteomyelitis). 84 A published Cochrane review of a small number of appropriate studies has suggested equipoise, 85 except in patients with septicaemia.
Attempts to assess the efficacy of specific antibiotic regimens for diabetic foot ulcers are complicated by the heterogeneous nature of study design. In many studies, it is unclear the extent to which "usual care" includes core factors such as sharp debridement and offloading.
In addition, those with osteomyelitis and peripheral arterial disease are frequently excluded from studies and there is a lack of consistency with respect to reporting of severity criteria and end-point data. 86, 87 The paucity of novel antibiotic therapies is an important factor in the ongoing clinical decision-making process. This is particularly pertinent in the current climate of admission avoidance and outpatient management. The decision to utilise empirical therapy coupled with potentially suboptimal tissue sampling creates an opportunity for more prolonged use of broad-spectrum agents. These cannot necessarily be adequately rationalised before inducing antibiotic resistance in the infecting pathogen. They may even encourage commensal proliferation which could become problematic in chronic wound situations.
The diabetic foot ulcer prevalence of MRSA of between 20% and 30% in some countries 88 Chronic kidney disease is a common comorbidity in people with diabetes which also increases the risk of foot ulceration. 104 Direct nephrotoxic effects from agents with a narrow therapeutic index such as gentamicin require close monitoring. In addition, side effects such as hyperkalaemia occur more frequently in people with reduced renal function. 105 Consideration of renal function is therefore encouraged in both empirical antibiotic choice and dosing in those with chronic kidney disease and in all patients the authors recommend a maximum of 4 days of empirical gentamicin 106 (Table 2 ). An alternative strategy to limit nephrotoxicity is to consider synergistic dosing of gentamicin in combination with other agents. Specialist antimicrobial advice should be sought in this case.
| OUTPATIENT INTRAVENOUS ANTIBIOTIC THERAPY (OPAT)
Inevitably, a minority of patients with deep-seated diabetic foot infections will require prolonged IV therapy because of organism susceptibility or intolerance/failure of an otherwise appropriate oral regimen.
In these circumstances and presuming suitability, OPAT can be considered. The resultant reduction in inpatient stay is associated with reduced healthcare-associated costs and complications as well as improved patient satisfaction. 107 A number of antibiotics lend themselves to ease of administration in the OPAT setting including the once daily agents ceftriaxone, ertapenem, daptomycin and teicoplanin. Depending on the OPAT service, IV therapy may be self (or carer) administered or via specialised infusion devices. UK good practice recommendations for safe OPAT practice have been published. 108 In the context of severe infection (Tables 1 and 2) , OPAT should only be considered as a "step-down" option once the individual is clinically stable enough for outpatient management and assuming no appropriate oral therapy.
| CONCLUSIONS
Foot ulceration in people with diabetes continues to be challenging for both those affected and the healthcare professionals who look after them. Identification and treatment of infection is an important step in management although despite useful progress in both imaging of deep tissues and detection of pathogens, clinical assessment using parameters such as "sausage" digits, probe-to-bone testing and IDSA infection grading criteria (Table 1) 25,109 remain the most useful and appropriate guidelines. Key points with respect to treating DFI are summarised in Figure 2 . Whilst narrow spectrum, tailored antibiotic therapy is recommended, it is accepted that empirical treatment is often required, ideally after appropriate tissue sampling (Figure 3 ).
In the absence of novel antibiotics, the attached guideline should prove to be a useful tool in supporting clinical decision-making with respect to antimicrobial therapy (Table 2) . Antibiotic choice should then be reviewed once culture results become available.
